Compound atlas
Healing

PNC-27

Peptide
Half-life
1h
approx. mean t½
Dose range
Research
typical, not prescriptive
Category
Healing
primary use-case
Single-dose decay
t½ = 1h · first-order model
~4h
to clear
1× t½
50%
remaining
2× t½
25%
remaining
~4× t½
6%
remaining
0%25%50%75%100%0m1.2h2.4h3.6h4.8h6h

How a single dose clears, assuming first-order elimination. The half-life is the biggest driver of how often you dose — start a cycle to see your own cumulative concentration curve.

Overview

A research peptide studied in vitro for selectively destroying cancer cells. Purely experimental — no human efficacy or safety data.

Mechanism of action

Contains an HDM-2-binding domain plus a membrane-penetrating sequence that forms pores selectively in cancer-cell membranes in lab models.

Typical protocol

Laboratory research only; no established human protocol.

Storage

Reconstituted: refrigerated; protect from light.

Disclaimer

This page summarizes publicly available information. None of it constitutes medical advice, prescription, or recommendation to acquire, possess, or use any compound. Many peptides described are research chemicals not approved for human use in the EU. Consult a licensed physician.